Iris Acquisition Corp
IRAA
Other OTC6.43
USD
-0.56
- -
CIK
0001831874
ISIN
US89601Y1010
CUSIP
89601Y101
Return %
Stock
S&P500
1Y
-40.46
18.21
3Y
-34.25
64.38
5Y
-35.89
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sumit Mehta
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2700 19th Street San Francisco CA United States of America 94110
- IPO Date
- May 26, 2021
- CIK
- 0001831874
- Website
- tribecapitalgrowthcorp.com
- Similar Companies
- Business
- Iris Acquisition Corp Iris Acquisition Corp (IRAA) is a Cayman Islands-based blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses; the company conducts no significant operations and generates no revenues prior to completing an initial business combination. Iris Acquisition Corp offers no products or services beyond its SPAC structure, which facilitates public listings for target companies through merger transactions; it targets businesses across various industries without predefined sector limitations. Incorporated in 2020 and headquartered in George Town, Cayman Islands, the company operates as a subsidiary of Iris Acquisition Holdings LLC and was formerly known as Tribe Capital Growth Corp I, changing its name in July 2022. In recent developments, Iris Acquisition Corp entered into a definitive business combination agreement with Liminatus Pharma LLC, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, initially announced on November 30, 2022; the transaction, which includes commitments for up to $15 million in PIPE financing and involves multiple amendments to extend deadlines—including to June 30, 2025—remains pending stockholder approval and customary closing conditions as of early 2025, with the combined entity expected to operate as Liminatus Pharma, Inc. and list on the Nasdaq Capital Market. The company has navigated regulatory extensions for Nasdaq listing compliance, undergone management changes including the appointment of Iris Equity Holdings LLC as managing member following a loan from Hannah Immunotherapeutics LLC, and terminated certain financing arrangements such as a convertible note subscription while amending equity commitments to support the proposed merger.
Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments